Combined treatment with these inhibitors amplified autophagy-related gene expression, suggesting possible synergistic effects.Preclinical studies on the efficacy of PI3K/AKT/mTOR inhibitors in AML cell lines and primary AML cells have yielded promising results [9]. The gene discussed is PIK3CA; the disease is acute myeloid leukemia.